We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Agilon Health (AGL) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Agilon Health (AGL - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Agilon Health is a member of the Medical sector. This group includes 917 individual stocks and currently holds a Zacks Sector Rank of #11. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Agilon Health is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AGL's full-year earnings has moved 17.2% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, AGL has gained about 384.4% so far this year. Meanwhile, the Medical sector has returned an average of -0.7% on a year-to-date basis. This means that Agilon Health is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is CRISPR Therapeutics AG (CRSP - Free Report) . The stock is up 3% year-to-date.
In CRISPR Therapeutics AG's case, the consensus EPS estimate for the current year increased 8.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Agilon Health is a member of the Medical Services industry, which includes 70 individual companies and currently sits at #105 in the Zacks Industry Rank. On average, this group has gained an average of 2.7% so far this year, meaning that AGL is performing better in terms of year-to-date returns.
In contrast, CRISPR Therapeutics AG falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 449 stocks and is ranked #178. Since the beginning of the year, the industry has moved +1.3%.
Agilon Health and CRISPR Therapeutics AG could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
View the Zacks #1 Rank List
Image: Bigstock
Is Agilon Health (AGL) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Agilon Health (AGL - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Agilon Health is a member of the Medical sector. This group includes 917 individual stocks and currently holds a Zacks Sector Rank of #11. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Agilon Health is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AGL's full-year earnings has moved 17.2% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, AGL has gained about 384.4% so far this year. Meanwhile, the Medical sector has returned an average of -0.7% on a year-to-date basis. This means that Agilon Health is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is CRISPR Therapeutics AG (CRSP - Free Report) . The stock is up 3% year-to-date.
In CRISPR Therapeutics AG's case, the consensus EPS estimate for the current year increased 8.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Agilon Health is a member of the Medical Services industry, which includes 70 individual companies and currently sits at #105 in the Zacks Industry Rank. On average, this group has gained an average of 2.7% so far this year, meaning that AGL is performing better in terms of year-to-date returns.
In contrast, CRISPR Therapeutics AG falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 449 stocks and is ranked #178. Since the beginning of the year, the industry has moved +1.3%.
Agilon Health and CRISPR Therapeutics AG could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.